Intec Pharma (NASDAQ:NTEC)‘s stock had its “hold” rating reiterated by research analysts at HC Wainwright in a report issued on Monday, Stock Target Advisor reports.
Several other analysts also recently issued reports on NTEC. Zacks Investment Research raised shares of Intec Pharma from a “hold” rating to a “buy” rating and set a $0.75 target price on the stock in a research note on Wednesday, October 16th. LADENBURG THALM/SH SH reaffirmed a “hold” rating on shares of Intec Pharma in a research report on Monday, August 12th. ValuEngine downgraded Intec Pharma from a “buy” rating to a “hold” rating in a report on Friday, November 1st. Finally, Roth Capital downgraded Intec Pharma from a “buy” rating to a “neutral” rating and lowered their price target for the company from $10.00 to $1.00 in a report on Friday, October 11th. Six equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $9.96.
NTEC stock opened at $0.65 on Monday. The firm has a market capitalization of $21.34 million, a P/E ratio of -0.46 and a beta of -0.13. Intec Pharma has a 52-week low of $0.41 and a 52-week high of $9.25. The company’s 50 day simple moving average is $0.63 and its 200-day simple moving average is $1.95.
Several hedge funds have recently bought and sold shares of NTEC. JPMorgan Chase & Co. acquired a new stake in shares of Intec Pharma during the second quarter worth approximately $125,000. Migdal Insurance & Financial Holdings Ltd. increased its stake in Intec Pharma by 25.9% in the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 729,193 shares of the biotechnology company’s stock valued at $3,165,000 after buying an additional 150,000 shares during the period. Renaissance Technologies LLC acquired a new position in Intec Pharma in the 2nd quarter valued at approximately $593,000. Morgan Stanley lifted its position in Intec Pharma by 38.4% in the 2nd quarter. Morgan Stanley now owns 81,931 shares of the biotechnology company’s stock worth $356,000 after buying an additional 22,715 shares in the last quarter. Finally, River & Mercantile Asset Management LLP purchased a new stake in Intec Pharma in the 2nd quarter worth approximately $1,230,000. Institutional investors and hedge funds own 17.21% of the company’s stock.
About Intec Pharma
Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism.
Further Reading: What does the Dogs of the Dow mean?
Receive News & Ratings for Intec Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma and related companies with MarketBeat.com's FREE daily email newsletter.